Evidence map›Paper›PMID 30478149›Full record

ArticleMolecular cancer therapeutics2019

3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers.

Dylan T Jones, Alessandro Valli, Syed Haider, Qifeng Zhang, Elizabeth A Smethurst, Zachary T Schug, Barrie Peck, Eric O Aboagye, Susan E Critchlow, Almut Schulze and 3 more

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Molecular cancer therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Mass Spectrometry-Based Applications of Spheroids in Cancer Biology.Annual review of analytical chemistry (Palo Alto, Calif.) · 2025
    Review
  5. Review
  6. Review
  7. Cancer 3D Models for Metallodrug Preclinical Testing.International journal of molecular sciences · 2023
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 5 countries.

Dylan T JonesTarget Discovery Institute, NDM Research Building, Old Road Campus, Headington, Oxford, United Kingdom. dylan_t_jones@yahoo.co.uk.
Alessandro ValliMolecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
Syed HaiderMolecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
Qifeng ZhangBabraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
Elizabeth A SmethurstMolecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
Zachary T SchugThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0003-4197-8227
Barrie PeckThe Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Eric O AboagyeDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom.
Susan E CritchlowBioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
Almut SchulzeTheodor-Boveri-Institute, Bicenter, Am Hubland, Würzburg, Germany; and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.ORCID 0000-0002-8199-6422
Eyal GottliebRappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.ORCID 0000-0002-9770-0956
Michael J O WakelamBabraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
Adrian L HarrisMolecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
Babraham Institute · GBJohn Radcliffe Hospital · GBAlzheimer’s Research UK · GBAstraZeneca (United Kingdom) · GBBreast Cancer Now · GBBreast Cancer Research Foundation · USComprehensive Cancer Center Mainfranken · DEHammersmith Hospital · GBMarks and Spencer (United Kingdom) · GBTechnion – Israel Institute of Technology · ILThe Wistar Institute · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Biotechnology and Biological Sciences Research Council BBS/E/B/000C0415Biotechnology and Biological Sciences Research Council BBS/E/B/000C0419Cancer Research UK 18974Cancer Research UK C602/A18974NCI NIH HHS P30 CA010815
6 · The paper itself

Abstract

Tumor cells exhibit altered lipid metabolism compared with normal cells. Cell signaling kinases are important for regulating lipid synthesis and energy storage. How upstream kinases regulate lipid content, versus direct targeting of lipid-metabolizing enzymes, is currently unexplored. We evaluated intracellular lipid concentrations in prostate and breast tumor spheroids, treated with drugs directly inhibiting metabolic enzymes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), diacylglyceride acyltransferase (DGAT), and pyruvate dehydrogenase kinase (PDHK), or cell signaling kinase enzymes PI3K, AKT, and mTOR with lipidomic analysis. We assessed whether baseline lipid profiles corresponded to inhibitors' effectiveness in modulating lipid profiles in three-dimensional (3D) growth and their relationship to therapeutic activity. Inhibitors against PI3K, AKT, and mTOR significantly inhibited MDA-MB-468 and PC3 cell growth in two-dimensional (2D) and 3D spheroid growth, while moderately altering lipid content. Conversely, metabolism inhibitors against FASN and DGAT altered lipid content most effectively, while only moderately inhibiting growth compared with kinase inhibitors. The FASN and ACC inhibitors' effectiveness in MDA-MB-468, versus PC3, suggested the former depended more on synthesis, whereas the latter may salvage lipids. Although baseline lipid profiles did not predict growth effects, lipid changes on therapy matched the growth effects of FASN and DGAT inhibitors. Several phospholipids, including phosphatidylcholine, were also upregulated following treatment, possibly via the Kennedy pathway. As this promotes tumor growth, combination studies should include drugs targeting it. Two-dimensional drug screening may miss important metabolism inhibitors or underestimate their potency. Clinical studies should consider serial measurements of tumor lipids to prove target modulation. Pretherapy tumor classification by

Indexed as

Acetyl-CoA CarboxylaseBreast NeoplasmsCell Culture TechniquesCell Line, TumorCell ProliferationCell SurvivalDiacylglycerol O-AcyltransferaseEnzyme InhibitorsFatty Acid Synthase, Type IFemaleHumansLipid MetabolismMalePhospholipidsProstatic NeoplasmsProtein Kinase InhibitorsACACA protein, humanAcetyl-CoA CarboxylaseDGAT1 protein, humanDiacylglycerol O-AcyltransferaseEnzyme InhibitorsFASN protein, humanFatty Acid Synthase, Type IPhospholipidsProtein Kinase Inhibitors

Identifiers

PMID30478149
PMCPMC6611711
OpenAlexW2903482389

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.